Scintillator-Based Nanohybrids with Sacrificial Electron Prodrug for Enhanced X-ray-Induced Photodynamic Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30052464.
- Also identified by DOI 10.1021/acs.nanolett.8b02409.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
X-ray-induced photodynamic therapy (X-PDT) has high depth of penetration and has considerable potential for applications in cancer therapy. Scintillators and heavy metals have been adopted to absorb X-rays and transmit the energy to photosensitizers. However, the low efficiency of converting X-rays to reactive oxygen species (ROS) presents a challenge for the use of X-PDT to cure cancer. In this study, a new method based on LiLuF<sub>4</sub>:Ce@SiO<sub>2</sub>@Ag<sub>3</sub>PO<sub>4</sub>@Pt(IV) nanoparticles (LAPNP) is presented that could be used to enhance the curative effects of X-PDT. To make full use of the fluorescence produced by nanoscintillators (LiLuF<sub>4</sub>:Ce), a cisplatin prodrug Pt(IV) was utilized as a sacrificial electron acceptor to increase the yield of hydroxyl radicals (·OH) by increasing the separation of electrons and holes in photosensitizers (Ag<sub>3</sub>PO<sub>4</sub>). Additionally, cisplatin is produced upon the acceptance of electrons by Pt(IV) and further enhances the damage caused by ·OH. Via two-step amplification, the potential of LAPNP to enhance the effects of X-PDT has been demonstrated.
Medical subject headings
- Antineoplastic Agents
- Cisplatin
- Neoplasms
- Phosphates
- Photochemotherapy
- Photosensitizing Agents
- Prodrugs
- Silver Compounds